Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: A randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 1144-1147

  Hartkamp, A ^a,b   Geenen, Rinie ^a,c   Godaert, G L R ^c   Bijl, M ^d   Bijlsma, J W J ^a   Derksen, R H W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PRASTERONE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WELLBEING;

ADULT; AGED; DEHYDROEPIANDROSTERONE; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; TESTOSTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952793334     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117036     Document Type: Article

References (20)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96.
2. Omdal R, Mellgren SI, Koldingsnes W, et al. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002;29:482-6.
3. Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1249-54.
4. Derksen RH. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. Semin Arthritis Rheum 1998;27:335-47.
5. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004;13:635-8.
6. Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987;30:241-8.
7. van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994;37:1305-10.
8. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005;38:531-40.
9. Thumboo J, Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000;27:1414-20. (Pubitemid 30354037)
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
12. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
13. Ware JE, Kosinski M, Keller SD. Physical and mental health summary scales - a user's manual. Boston, Massachusetts: New England Medical Center, The Health Institute, 1994.
14. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
15. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
16. Hartkamp A, Geenen R, Godaert GL, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Ann Rheum Dis 2008;67:91-7.
17. Chang DM, Lan JL, Lin HY, et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2924-7.
18. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
19. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004;50:2858-68.
20. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002;46:1820-9.